Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2009
At a glance
- Drugs CX 157 (Primary)
- Indications Major depressive disorder
- Focus Biomarker; Pharmacodynamics
- Sponsors CeNeRx BioPharma
- 07 Dec 2009 New trial record.
- 04 Nov 2009 Results reported in Neuropsychopharmacology.
- 04 Nov 2009 Primary endpoint 'Enzyme inhibition' has been met.